Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the g... Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. Show more
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (βFortressβ or βCompanyβ), an innovative biopharmaceutical company focused on acquiring and advancing assets to...
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (βJourney Medicalβ or βthe Companyβ) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (βFortressβ), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance...
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (βJourney Medicalβ or βthe Companyβ) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (βAvenueβ or the βCompanyβ), a specialty pharmaceutical company focused on the development and...
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab...
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase...
- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 β - Raised $4.4 million in gross...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.52 | -27.2251308901 | 1.91 | 2.04 | 1.355 | 1743202 | 1.50213546 | CS |
4 | -0.65 | -31.862745098 | 2.04 | 2.09 | 1.355 | 615723 | 1.59618238 | CS |
12 | -0.3 | -17.7514792899 | 1.69 | 2.89 | 1.355 | 395683 | 1.83818678 | CS |
26 | -0.53 | -27.6041666667 | 1.92 | 2.89 | 1.355 | 286487 | 1.84097454 | CS |
52 | -3.11 | -69.1111111111 | 4.5 | 5.2485 | 1.24 | 421809 | 2.23832865 | CS |
156 | -52.31 | -97.4115456238 | 53.7 | 57.15 | 1.24 | 501893 | 14.12239398 | CS |
260 | -20.36 | -93.6091954023 | 21.75 | 91.5 | 1.24 | 645063 | 34.87246167 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.